Describing the Patient Journey of Women with Claims for Uterine Fibroids and Heavy Menstrual Bleeding Using a Commercial Database (2011–2020)

References

• Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100–107. doi:10.1067/mob.2003.99
   PubMed Web of Science ®Google Scholar
• Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124(10):1501–1512. doi:10.1111/1471-0528.14640
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians & Gynecologists. Management of symptomatic uterine leiomyomas: ACOG practice bulletin, number 228. Obstet Gynecol. 2021;137(6):e100–e115. doi:10.1097/AOG.0000000000004401
   PubMedGoogle Scholar
• Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Women's Health. 2012;12:6. doi:10.1186/1472-6874-12-6
   PubMed Web of Science ®Google Scholar
• De La Cruz MS, Buchanan EM. Uterine fibroids: diagnosis and treatment. Am Fam Physician. 2017;95(2):100–107.
   PubMed Web of Science ®Google Scholar
• Evans P, Brunsell S. Uterine fibroid tumors: diagnosis and treatment. Am Fam Physician. 2007;75(10):1503–1508.
   PubMed Web of Science ®Google Scholar
• Lewis TD, Malik M, Britten J, San Pablo AM, Catherino WH. A comprehensive review of the pharmacologic management of uterine leiomyoma. Biomed Res Int. 2018;2018:2414609. doi:10.1155/2018/2414609
   PubMed Web of Science ®Google Scholar
• Khan AT, Shehmar M, Gupta JK. Uterine fibroids: current perspectives. Int J Womens Health. 2014;6:95–114. doi:10.2147/IJWH.S51083
   PubMedGoogle Scholar
• MYFEMBREE®. Prescribing information. Myovant Sciences Inc; 2021. Available from: https://www.myovant.com/wp-content/uploads/2023/01/Approved-MYFEMBREE-PI-and-PPI_27January2023.pdf. Accessed May 4, 2023.
   Google Scholar
• ORIAHNN. Prescribing information. AbbVie Inc; 2020. Available from: https://www.rxabbvie.com/pdf/oriahnn_pi.pdf. Accessed May 4, 2023.
   Google Scholar
• Al-Hendy A, Lukes AS, Poindexter AN, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med. 2021;384(7):630–642. doi:10.1056/NEJMoa2008283
   PubMed Web of Science ®Google Scholar
• Al-Hendy A, Stewart EA, Venturella R, Hunsche E, Zhao X, Lukes AS. Relugolix combination therapy improves bulk symptoms of uterine fibroids* through 24 week treatment. presented at: society of Endometriosis and Uterine Disorders (SEUD) Annual Congress. Athens: Greece; 2022.
   Google Scholar
• Stewart EA, Lukes AS, Venturella R, et al. Relugolix combination therapy for uterine leiomyoma-associated pain in the LIBERTY randomized trials. Obstet Gynecol. 2022;139(6):1070–1081. doi:10.1097/AOG.0000000000004787
   PubMed Web of Science ®Google Scholar
• Bonine NG, Banks E, Harrington A, Vlahiotis A, Moore-Schiltz L, Gillard P. Contemporary treatment utilization among women diagnosed with symptomatic uterine fibroids in the United States. BMC Womens Health. 2020;20(1):174. doi:10.1186/s12905-020-01005-6
   PubMed Web of Science ®Google Scholar
• Stewart EA, Laughlin-Tommaso SK, Catherino WH, Lalitkumar S, Gupta D, Vollenhoven B. Uterine fibroids. Nat Rev Dis Primers. 2016;2:16043. doi:10.1038/nrdp.2016.43
   PubMed Web of Science ®Google Scholar
• McKain L, Edsall K, Dufour R, Lickert C. Treatment patterns in patients with uterine fibroids with and without a diagnosis of heavy menstrual bleeding: results from a large U.S. claims database. J Womens Health. 2022;32(3):332–340. doi:10.1089/jwh.2022.0056
   Web of Science ®Google Scholar
• Schlaff WD, Ackerman RT, Al-Hendy A, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382(4):328–340. doi:10.1056/NEJMoa1904351
   PubMed Web of Science ®Google Scholar
• Lee DW, Ozminkowski RJ, Carls GS, Wang S, Gibson TB, Stewart EA. The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids. J Occup Environ Med. 2007;49(5):493–506. doi:10.1097/JOM.0b013e31805f6cf2
   PubMed Web of Science ®Google Scholar
• Fuldeore M, Yang H, Soliman AM, Winkel C. Healthcare utilization and costs among women diagnosed with uterine fibroids: a longitudinal evaluation for 5 years pre- and post-diagnosis. Curr Med Res Opin. 2015;31(9):1719–1731. doi:10.1185/03007995.2015.1069738
   PubMed Web of Science ®Google Scholar
• Artiga S, Latoya H, Orgera K, Damico A. Health coverage by race and ethnicity, 2010–2019. Kaiser Family Foundation. Available from: https://www.kff.org/racial-equity-and-health-policy/issue-brief/health-coverage-by-race-and-ethnicity/. Accessed September 23, 2022.
   Google Scholar
• United States Census Bureau. Quick facts. Available from: https://www.census.gov/quickfacts/US. Accessed October 21, 2022.
   Google Scholar
• Soliman AM, Yang H, Du EX, Kelkar S, Winkel C. A systematic literature review of comorbidities and symptoms among uterine fibroids patients between 2000 and 2013. Value Health. 2016;19(2016):A172.
   Google Scholar
• Fuldeore MJ, Soliman AM. Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis. Int J Women's Health. 2017;9:403–411. doi:10.2147/IJWH.S133212
   PubMed Web of Science ®Google Scholar
• Uimari O, Jarvela I, Ryynanen M. Do symptomatic endometriosis and uterine fibroids appear together? J Hum Reprod Sci. 2011;4(1):34–38. doi:10.4103/0974-1208.82358
   PubMedGoogle Scholar
• Freytag D, Gunther V, Maass N, Alkatout I. Uterine fibroids and infertility. Diagnostics. 2021;11:8. doi:10.3390/diagnostics11081455
   Web of Science ®Google Scholar
• Kinay T, Ozturk Basarir Z, Firtina Tuncer S, Akpinar F, Kayikcioglu F, Koc S. Prevalence of endometrial polyps coexisting with uterine fibroids and associated factors. Turk J Obstet Gynecol. 2016;13(1):31–36. doi:10.4274/tjod.36043
   PubMedGoogle Scholar
• Faerstein E, Szklo M, Rosenshein NB. Risk factors for uterine leiomyoma: a practice-based case-control study. II. Atherogenic risk factors and potential sources of uterine irritation. Am J Epidemiol. 2001;153(1):11–19. doi:10.1093/aje/153.1.11
   PubMedGoogle Scholar
• Charles H, Groenwald M. Comorbid medical conditions in women undergoing uterine artery embolization for symptomatic uterine fibroids and adenomyosis. J Vasc Interv Radiol. 2013;24(4):S152. doi:10.1016/j.jvir.2013.01.381
   Google Scholar
• Wang A, Wang S, Owens CD, Vora JB, Diamond MP. Health care costs and treatment patterns associated with uterine fibroids and heavy menstrual bleeding: a claims analysis. J Women's Health. 2022;31(6):856–863. doi:10.1089/jwh.2020.8983
   PubMed Web of Science ®Google Scholar
• Duyar S, Tsai S, Milad MP, Chaudhari A. Attitudes and beliefs about hysterectomy in patients with uterine fibroids. J Minim Invasive Gynecol. 2023. doi:10.1016/j.jmig.2023.05.012
   PubMed Web of Science ®Google Scholar
• Wegienka G, Stewart EA, Nicholson WK, et al. Black women are more likely than white women to schedule a uterine-sparing treatment for leiomyomas. J Women's Health. 2021;30(3):355–366. doi:10.1089/jwh.2020.8634
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians & Gynecologists. ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol. 2008;112:387–400. doi:10.1097/AOG.0b013e318183fbab
   PubMedGoogle Scholar
• Jacoby VL, Fujimoto VY, Giudice LC, Kuppermann M, Washington AE. Racial and ethnic disparities in benign gynecologic conditions and associated surgeries. Am J Obstet Gynecol. 2010;202(6):514–521. doi:10.1016/j.ajog.2010.02.039
   PubMed Web of Science ®Google Scholar
• Laughlin-Tommaso SK, Jacoby VL, Myers ER. Disparities in fibroid incidence, prognosis, and management. Obstet Gynecol Clin North Am. 2017;44(1):81–94. doi:10.1016/j.ogc.2016.11.007
   PubMed Web of Science ®Google Scholar